Visanji Mika'il, Belley-Côté Emilie P, Pandey Ashok, Amit Yael, McClure Graham R, Young Jack, Um Kevin J, Oraii Alireza, Healey Jeff S, Whitlock Richard P, McIntyre William F
Department of Medicine, McMaster University, Hamilton, ON, Canada.
Population Health Research Institute, Hamilton, ON, Canada.
Interdiscip Cardiovasc Thorac Surg. 2024 Dec 3;39(6). doi: 10.1093/icvts/ivae195.
Atrial fibrillation is the most common complication of cardiac surgery and occurs frequently in patients without a history of the arrhythmia. We conducted a systematic review and meta-analysis of randomized controlled trials to assess whether prophylactic ablation during cardiac surgery in patients without a history of atrial fibrillation prevents atrial fibrillation.
We searched CENTRAL, MEDLINE and Embase from inception to August 2024. We included randomized trials of adults without a history of atrial fibrillation undergoing cardiac surgery. The intervention of interest was ablation during surgery. We pooled data using random-effects models. The primary outcome was new-onset early postoperative atrial fibrillation within 30 days following surgery. The key secondary outcome was incident clinical atrial fibrillation at follow-up (minimum 6 months). We assessed risk of bias using the Cochrane Collaboration's risk of bias tool v.2 and evidence quality using Grading of Recommendations, Assessment, Development and Evaluation (GRADE).
We included 7 trials (n = 687). The intervention was pulmonary vein isolation in 6 trials and ganglion plexi ablation in 1. Patients who received prophylactic ablation were less likely to have early postoperative atrial fibrillation (21% vs 37%, risk ratio [RR] 0.5, 95% confidence interval 0.3-0.8, I2 = 64%) and incident clinical atrial fibrillation at longest follow-up (range 6 months-2 years; 3% vs 10%, RR 0.3, 95% confidence interval 0.2-0.7, I2 = 0%). The quality of evidence was low.
Prophylactic ablation during cardiac surgery may prevent atrial fibrillation in patients without a history of the arrhythmia. A definitive randomized trial is needed to confirm effects and safety.
心房颤动是心脏手术最常见的并发症,且常发生于无心律失常病史的患者。我们进行了一项随机对照试验的系统评价和荟萃分析,以评估在无心房颤动病史的患者进行心脏手术期间进行预防性消融是否可预防心房颤动。
我们检索了从创刊至2024年8月的CENTRAL、MEDLINE和Embase数据库。我们纳入了无心房颤动病史的成年患者接受心脏手术的随机试验。感兴趣的干预措施是手术期间的消融。我们使用随机效应模型汇总数据。主要结局是术后30天内新发的早期术后心房颤动。关键次要结局是随访时(至少6个月)发生的临床心房颤动。我们使用Cochrane协作网的偏倚风险工具v.2评估偏倚风险,并使用推荐分级、评估、制定与评价(GRADE)评估证据质量。
我们纳入了7项试验(n = 687)。6项试验中的干预措施为肺静脉隔离,1项试验为神经节丛消融。接受预防性消融的患者术后早期发生心房颤动的可能性较小(21% 对37%,风险比[RR] 0.5,95%置信区间0.3 - 0.8,I² = 64%),且在最长随访期(6个月至2年)发生临床心房颤动的可能性也较小(3% 对10%,RR 0.3,95%置信区间0.2 - 0.7,I² = 0%)。证据质量低。
心脏手术期间的预防性消融可能预防无心律失常病史患者发生心房颤动。需要进行确定性随机试验以确认其效果和安全性。